22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
Antitrust agencies around the world are adjusting to the policies and procedures they quickly implem...
Read More >
On the eve of the holidays, the National Labor Relations Board (NLRB) delivered an early Christmas p...
Read More >
It can take almost a lifetime to build a sterling reputation in the retirement plan industry as a pl...
Read More >
As we previously reported, on June 13, the Departments of Health and Human Services, Labor, and the ...
Read More >
Parties to merger, acquisition, and financing agreements may be considering whether the COVID-19 pan...
Read More >
Welcome to Exiger Week on Compliance and Coronavirus. As the Voice of Compliance, I wanted to start ...
Read More >